ストックスクリーナーアプリを入手
2.87
0.69%
-0.010
前日終値:
$2.88
開ける：
$2.87
24時間の取引高:
24,383
Relative Volume:
0.11
時価総額：
$101.53M
収益：
-
当期純損益:
$-27.66M
株価収益率:
-3.0211
EPS:
-0.95
ネットキャッシュフロー:
$-24.36M
1週間 パフォーマンス:
+5.93%
1か月 パフォーマンス:
-7.14%
6か月 パフォーマンス:
-3.38%
1年 パフォーマンス:
-15.88%
1日の値動き範囲:
$2.77
$3.0099
1週間の範囲:
$2.72
$3.1541
52週間の値動き範囲:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
名前
Genelux Corp
セクター
電話
805-267-9889
住所
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
GNLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.86 | 101.53M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.38 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
601.61 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.94 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.54 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.72 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-29 | 開始されました | Guggenheim | Buy |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-11-27 | 開始されました | H.C. Wainwright | Buy |
| 2023-09-12 | 開始されました | Maxim Group | Buy |
| 2023-02-15 | 開始されました | The Benchmark Company | Speculative Buy |
Genelux Corp (GNLX) 最新ニュース
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Raymond James Financial Inc. Takes $41,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Benchmark maintains $25 target on Genelux stock, optimistic on trials - Investing.com
Benchmark maintains $25 target on Genelux stock, optimistic on trials By Investing.com - Investing.com India
What is HC Wainwright’s Forecast for Genelux Q1 Earnings? - Defense World
Analysts Offer Predictions for Genelux Q1 Earnings - Defense World
Genelux (NASDAQ:GNLX) Given Buy Rating at HC Wainwright - Defense World
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements - TipRanks
H.C. Wainwright maintains Buy on Genelux shares, target at $30 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Genelux shares, target at $30 - Investing.com
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Brokers Set Expectations for Genelux FY2024 Earnings - Defense World
Research Analysts Set Expectations for Genelux Q1 Earnings - The AM Reporter
Genelux reports FY24 EPS (95c), consensus (88c) - TipRanks
FDA Green Light: Genelux's Cancer Drug Olvi-Vec Advances as 2024 Data Shows 71% Disease Control - Stock Titan
GENELUX Corp SEC 10-K Report - TradingView
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance
Genelux (GNLX) Projected to Post Quarterly Earnings on Friday - Defense World
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. - TipRanks
What is HC Wainwright’s Estimate for Genelux Q1 Earnings? - Defense World
Benchmark maintains $25 target on Genelux following trial data - Investing.com
Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Genelux stock holds Buy rating, $30 target from H.C. Wainwright - Investing.com India
Genelux prices 3M shares at $3.50 in underwritten public offering - TipRanks
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec - TipRanks
Genelux announces alignment with FDA of approval pathway for Olvi-Vec - TipRanks
Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial - MarketScreener
Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell - Nasdaq
Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study - Marketscreener.com
Genelux Prices $10.5 Million Stock Offering - MarketScreener
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock - GlobeNewswire
$10.5M Capital Raise: How Genelux Plans to Accelerate Cancer Drug Pipeline - Stock Titan
Breakthrough: Cancer Drug Achieves 79% Tumor Reduction in Advanced Lung Cancer Study - Stock Titan
Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D.A. Davidson & CO. Makes New $51,000 Investment in Genelux Co. (NASDAQ:GNLX) - Defense World
Apollon Wealth Management LLC Grows Stock Holdings in Genelux Co. (NASDAQ:GNLX) - Defense World
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - simplywall.st
Genelux Corporation (NASDAQ:GNLX) Announces CFO Transition and Appointment of New CFOGenelux Corporation, a leading biotechnology company, recently disclosed in an SEC filing that Lourie Zak has resigned as Chief Financial Officer, effective imm - Defense World
Genelux Corporation Announces Matt Pulisic Serves as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Genelux appoints new CFO as Lourie Zak departs - MSN
Genelux Corporation Announces New Chief Financial Officer - Markets Insider
GNLXGenelux Corp Latest Stock News & Market Updates - Stock Titan
Genelux appoints new CFO amid clinical advancements - Investing.com
Genelux Corp. Appoints New CFO Amid Leadership Change - TipRanks
Ex-Arrowhead & Amgen Executive Takes CFO Role at Genelux: Key Details on Strategic Appointment - Stock Titan
Oncolytic Viruses Market Expected to rise, 2034 | Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen - Barchart
Genelux (GNLX) Stock Price, News & Analysis - MarketBeat
We Think Genelux (NASDAQ:GNLX) Needs To Drive Business Growth Carefully - Yahoo Finance
Could Genelux's Olvi-Vec Emerge As A Powerful Tool In The Fight Against Difficult-to-treat Cancers? - RTTNews
Geode Capital Management LLC Has $749,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Corp (GNLX) 財務データ
収益
当期純利益
現金流量
EPS
0.63%
大文字化:
|
ボリューム (24 時間):